# Safety and Efficacy Study of Co-transfering of Mesenchymal Stem Cell and Regulatory T Cells in Treating End-stage Liver Disease

> **NCT03460795** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Nanjing Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **BIOLOGICAL:** MSC and Tregs

## Key facts

- **NCT ID:** NCT03460795
- **Lead sponsor:** Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03460795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03460795, "Safety and Efficacy Study of Co-transfering of Mesenchymal Stem Cell and Regulatory T Cells in Treating End-stage Liver Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03460795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*